danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics 
Welcome,         Profile    Billing    Logout  
 20 Diseases   7 Trials   7 Trials   223 News 


«1234
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Enrollment change, Trial termination:  AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites (clinicaltrials.gov) -  Apr 11, 2016   
    P2,  N=1, Terminated, 
    Not yet recruiting --> Recruiting | Phase classification: P1 --> P1b | N=40 --> 110 N=15 --> 1 | Recruiting --> Terminated; Study was closed because we could not find these types of patients.
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Trial initiation date, Trial primary completion date, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker:  MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) (clinicaltrials.gov) -  Jan 7, 2016   
    P1,  N=186, Not yet recruiting, 
    Trial primary completion date: Feb 2015 --> Jul 2016 Initiation date: Nov 2015 --> Apr 2016 | Trial primary completion date: Dec 2019 --> Apr 2021
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Trial completion, Enrollment change, Trial primary completion date, Metastases:  A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma (clinicaltrials.gov) -  Feb 19, 2015   
    P1,  N=58, Completed, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2018 --> Dec 2016 Active, not recruiting --> Completed | N=42 --> 58 | Trial primary completion date: Jul 2015 --> Feb 2015
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Enrollment closed, Trial primary completion date, Metastases:  A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma (clinicaltrials.gov) -  Dec 6, 2014   
    P1,  N=42, Active, not recruiting, 
    Active, not recruiting --> Completed | N=42 --> 58 | Trial primary completion date: Jul 2015 --> Feb 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Jul 2015
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Enrollment closed, Trial primary completion date, Metastases:  Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers (clinicaltrials.gov) -  Nov 12, 2014   
    P1/2,  N=80, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Feb 2015